HUP0105201A2 - Férfiklimax kezelése ösztrogén agonistákat/antagonistákat és tesztoszteront tartalmazó gyógyászati készítmények alkalmazásával - Google Patents

Férfiklimax kezelése ösztrogén agonistákat/antagonistákat és tesztoszteront tartalmazó gyógyászati készítmények alkalmazásával

Info

Publication number
HUP0105201A2
HUP0105201A2 HU0105201A HUP0105201A HUP0105201A2 HU P0105201 A2 HUP0105201 A2 HU P0105201A2 HU 0105201 A HU0105201 A HU 0105201A HU P0105201 A HUP0105201 A HU P0105201A HU P0105201 A2 HUP0105201 A2 HU P0105201A2
Authority
HU
Hungary
Prior art keywords
andropause
testosterone
treatment
antagonists
pharmaceutical compositions
Prior art date
Application number
HU0105201A
Other languages
English (en)
Inventor
David Burton Maclean
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HU0105201D0 publication Critical patent/HU0105201D0/hu
Publication of HUP0105201A2 publication Critical patent/HUP0105201A2/hu
Publication of HUP0105201A3 publication Critical patent/HUP0105201A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A találmány tárgyát ösztrogén agonista/antagonista és tesztoszteronkombinációjának alkalmazása képezi andropauza és a társuló állapotokkezelésére alkalmas gyógyszer előállítására. Az alkalmazott ösztrogénagonista/antagonista (I) általános képlettel írható le, ahol aképletben A jelentése CH2 vagy NR; B, D, E jelentése egymástólfüggetlenül CH vagy N; Y jelentése adott esetben helyettesítettfenil-, naftil-, cikloalkil-, cikloalkenilcsoport, 5- vagy 6-tagúheterociklusos, vagy 5- vagy 6-tagú heterociklusos csoporttalkondenzált Z1 jelentése -(CH2)pW(CH2)q-, -O(CH2)pCR5R6-, -O(OH2)pW(CH2) - vagy -S-CHR2CHR3-csoport; G jelentése -NR7R8csoport; W jelentése -CH2-; -CH=CH-, -O-; -NR2-, -S(O)n-; -CO-; -CR2(OH)-; -COnR2- -NR2-CO-csoport. Ó
HU0105201A 2000-11-30 2001-11-29 The treatment of andropause using pharmaceutical compositions containing estrogen agonists/antagonists and testosterone HUP0105201A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25007100P 2000-11-30 2000-11-30

Publications (3)

Publication Number Publication Date
HU0105201D0 HU0105201D0 (en) 2002-01-28
HUP0105201A2 true HUP0105201A2 (hu) 2002-12-28
HUP0105201A3 HUP0105201A3 (en) 2004-04-28

Family

ID=22946195

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0105201A HUP0105201A3 (en) 2000-11-30 2001-11-29 The treatment of andropause using pharmaceutical compositions containing estrogen agonists/antagonists and testosterone

Country Status (15)

Country Link
US (2) US20020115676A1 (hu)
EP (1) EP1210951B1 (hu)
JP (1) JP2002193809A (hu)
KR (1) KR20020042505A (hu)
AT (1) ATE288303T1 (hu)
AU (1) AU779964B2 (hu)
CA (1) CA2363935A1 (hu)
DE (1) DE60108710T2 (hu)
DK (1) DK1210951T3 (hu)
ES (1) ES2233570T3 (hu)
HU (1) HUP0105201A3 (hu)
IL (1) IL146701A0 (hu)
NZ (1) NZ515822A (hu)
PT (1) PT1210951E (hu)
ZA (1) ZA200109836B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8496960B2 (en) * 2001-10-23 2013-07-30 Purdue Pharma L.P. Terazosin transdermal device and methods
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
JP4938237B2 (ja) * 2002-12-18 2012-05-23 ラボラトワール ブザン アンテルナスィヨナル ４−ヒドロキシタモキシフェンによる乳房痛の治療
TWI330529B (en) * 2003-01-13 2010-09-21 Horphag Res Luxembourg Holding Sa A preparation for improving sperm quality or fertility,a kit comprising the same and uses thereof
JP2006525405A (ja) 2003-05-05 2006-11-09 ベン‐グリオン ユニバーシティ オブ ザ ネゲヴ リサーチ アンド デベロップメント オーソリティ 注入可能な架橋されたポリマー調製物およびその使用
DK1694319T3 (da) * 2003-12-15 2008-11-17 Besins Int Lab Anvendelser af 4-hydroxytamoxifen til fremstilling af et medikament til behandling af gynækomasti
EP1550440A1 (en) * 2003-12-15 2005-07-06 Laboratoires Besins International Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US20090169520A1 (en) * 2004-01-09 2009-07-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds, Pharmaceutical Compositions and Therapeutic Methods of Preventing and Treating Diseases and Disorders Associated With Amyloid Fibril Formation
WO2010000011A1 (en) * 2008-07-04 2010-01-07 The Heart Research Institute Ltd The use of androgens for vascular regeneration and endothelial repair
KR102335267B1 (ko) * 2017-03-16 2021-12-06 주식회사 자연과학기술 무지개송어 정소로부터 테스토스테론의 추출방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US585905A (en) * 1897-07-06 Frank bonileor
US5391557A (en) * 1993-10-15 1995-02-21 Eli Lilly And Company Methods for the treatment of peri-menopausal syndrome
US5589482A (en) * 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
DE19610635A1 (de) * 1996-03-11 1997-09-18 Schering Ag Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie
DE19619045C1 (de) * 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
US6653297B1 (en) * 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata

Also Published As

Publication number Publication date
EP1210951B1 (en) 2005-02-02
AU779964B2 (en) 2005-02-24
HU0105201D0 (en) 2002-01-28
EP1210951A2 (en) 2002-06-05
CA2363935A1 (en) 2002-05-30
DE60108710T2 (de) 2006-05-04
ZA200109836B (en) 2003-05-29
KR20020042505A (ko) 2002-06-05
DE60108710D1 (de) 2005-03-10
US20050288325A1 (en) 2005-12-29
PT1210951E (pt) 2005-04-29
ATE288303T1 (de) 2005-02-15
EP1210951A3 (en) 2003-09-24
IL146701A0 (en) 2002-07-25
DK1210951T3 (da) 2005-03-29
AU9516501A (en) 2002-06-06
JP2002193809A (ja) 2002-07-10
NZ515822A (en) 2003-05-30
HUP0105201A3 (en) 2004-04-28
ES2233570T3 (es) 2005-06-16
US20020115676A1 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
HUP0105201A2 (hu) Férfiklimax kezelése ösztrogén agonistákat/antagonistákat és tesztoszteront tartalmazó gyógyászati készítmények alkalmazásával
HUP0301336A2 (hu) Réztartalmú amin-oxidázok inhibitorai és alkalmazásuk gyógyszerkészítmények előállítására
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
CY1108573T1 (el) Ανταγωνιστες νρυυ5
HUP0303339A2 (hu) Heteroaril-karbamid neuropeptid Y Y5 receptor antagonisták, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
HUP0100388A2 (hu) Készítmények és eljárások csontritkulás kezelésére és a koleszterinszint csökkentésére
SE0202483D0 (sv) Chemical compounds
HUP0203458A2 (hu) Nociceptin ORL-1 receptor agonisták alkalmazása köhögés kezelésére és ezeket tartalmazó gyógyszerkészítmények
AR016762A1 (es) Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo
EA200401615A1 (ru) ИНГИБИТОРЫ АКТИВАЦИИ NF-kB
HUP0300616A2 (hu) Adamantánszármazékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
RU2007110629A (ru) Ингибиторы днк-пк
ATE332301T1 (de) Antivirale pyrazolopyridin verbindungen
AU2003228770A8 (en) Substituted pyrazolopyrimidines
ECSP034534A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
MXPA05012247A (es) Derivados de bencimidazol nuevos.
HUP0103203A2 (hu) Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
BRPI0514250A (pt) uso de um composto, composição farmacêutica que compreende o mesmo, compostos e método de tratamento
SE0200919D0 (sv) Chemical compounds
HUP0303737A2 (hu) 6-helyzetben szubsztituált indolinonok és alkalmazásuk kináz inhibitorokként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
MXPA05013758A (es) Composiciones farmaceuticas que incluyen una antihistamina y un estimulante y uso de las mismas.
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
NO20014855L (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
HUP0301116A2 (hu) (R)-n-[5-metil-8-(4-metil-1-piperazinil)-1,2,3,4-tetrahidro-2-naftil]-4-morfolino-benzamid új formája, eljárás az ellőállítására és ezt tartalmazó gyógyszerkészítmény

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees